-+ 0.00%
-+ 0.00%
-+ 0.00%
Aclaris Therapeutics starts Phase 2b trial of modzatinib for lichen planus
Share
Listen to the news
Aclaris Therapeutics starts Phase 2b trial of modzatinib for lichen planus
  • Aclaris Therapeutics initiated the Phase 2b ALPHA trial of modzatinib (ATI-2138) for moderate-to-severe lichen planus.
  • The placebo-controlled trial will evaluate two doses in approximately 100 participants whose disease is inadequately controlled with topical therapies.
  • Enrollment will begin with oral erosive lichen planus patients, with top-line results expected in the second half of 2027.
  • Modzatinib has FDA Fast Track designation for moderate-to-severe lichen planus, which has no FDA-approved therapies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160330PRIMZONEFULLFEED9877973) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending